This growth comes on the back of a steady market performance from 2017 to 2022, where the injection pen sector achieved a ...

California made a bold announcement that it would manufacture a state-branded, low-cost insulin. It still is not here.

Why it matters: More than 3.5 million Californians have diabetes, and insulin is a life-saving part of their disease ...

The FDA has approved Merilog (insulin-aspart-szjj), a biosimilar to Novolog, to improve glycemic control in patients with diabetes mellitus.

Both a 3-mL single-patient-use prefilled pen and ... like insulin. Increasing access to safe, effective and high-quality medications at potentially lower cost remains a continued priority for the FDA.

Merilog is expected to be available in July 2025, and Sanofi will provide Merilog to patients for $35 or less for a 30-day ...

In a landmark moment for Saudi Arabia’s healthcare sector, the Kingdom inaugurated its first local insulin manufacturing facility, a key milestone in advancing pharmaceutical self-sufficiency under ...

While the issue has fallen from the headlines after several moves to cap the cost, some patients with diabetes still often ...

The FDA has approved Merilog, the first-ever rapid-acting insulin biosimilar for diabetes treatment that helps manage blood ...

Third-quarter results for Medtronic (NYSE:MDT) included a timeline for a planned label expansion for its automated insulin ...